Stage IIA Prostate Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028878 (Stage IIA Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01656304Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone TherapyTreatment